Meridian Investment Counsel Inc. Sells 200 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Meridian Investment Counsel Inc. decreased its stake in Axon Enterprise, Inc. (NASDAQ:AXON) by 6.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,800 shares of the biotechnology company’s stock after selling 200 shares during the period. Meridian Investment Counsel Inc.’s holdings in Axon Enterprise were worth $1,664,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. B. Metzler seel. Sohn & Co. AG lifted its stake in Axon Enterprise by 13.2% in the fourth quarter. B. Metzler seel. Sohn & Co. AG now owns 6,123 shares of the biotechnology company’s stock valued at $3,639,000 after acquiring an additional 713 shares during the last quarter. Scalar Gauge Management LLC lifted its stake in Axon Enterprise by 44.2% in the 4th quarter. Scalar Gauge Management LLC now owns 27,400 shares of the biotechnology company’s stock valued at $16,284,000 after purchasing an additional 8,400 shares during the last quarter. Alliancebernstein L.P. grew its holdings in Axon Enterprise by 273.8% during the fourth quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company’s stock worth $659,128,000 after purchasing an additional 812,337 shares during the period. O Shaughnessy Asset Management LLC increased its position in Axon Enterprise by 51.7% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 5,447 shares of the biotechnology company’s stock worth $3,237,000 after buying an additional 1,856 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in Axon Enterprise by 697.1% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 7,357 shares of the biotechnology company’s stock valued at $4,372,000 after buying an additional 6,434 shares during the period. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Price Performance

Shares of NASDAQ AXON opened at $534.95 on Monday. The stock has a market capitalization of $40.99 billion, a PE ratio of 138.23, a P/E/G ratio of 5.17 and a beta of 1.12. Axon Enterprise, Inc. has a fifty-two week low of $273.52 and a fifty-two week high of $715.99. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The business has a fifty day moving average price of $589.62 and a two-hundred day moving average price of $550.61.

Insider Activity at Axon Enterprise

In other news, Director Jeri Williams sold 307 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $552.72, for a total value of $169,685.04. Following the completion of the transaction, the director now directly owns 1,627 shares in the company, valued at approximately $899,275.44. The trade was a 15.87 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total transaction of $271,831.50. Following the sale, the director now directly owns 6,929 shares of the company’s stock, valued at approximately $4,185,601.03. This trade represents a 6.10 % decrease in their position. The disclosure for this sale can be found here. 6.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

AXON has been the topic of a number of recent analyst reports. TD Cowen assumed coverage on Axon Enterprise in a report on Wednesday, January 8th. They set a “buy” rating and a $700.00 target price on the stock. The Goldman Sachs Group upped their price objective on shares of Axon Enterprise from $500.00 to $700.00 and gave the company a “buy” rating in a report on Monday, January 27th. Craig Hallum cut shares of Axon Enterprise from a “buy” rating to a “cautious” rating in a research note on Monday, March 10th. Northcoast Research lowered shares of Axon Enterprise from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 19th. Finally, JMP Securities restated an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $604.67.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.